Pancreatic Diseases Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Comments ยท 140 Views

The pancreas is a glandular organ located in the abdominal cavity that produces digestive enzymes and hormones such as insulin and glucagon. Pancreatic diseases can range from acute conditions such as pancreatitis to chronic conditions such as diabetes and pancreatic cancer. Although there

Pancreatic Diseases Overview

Pancreatic diseases can be broadly classified into three categories: pancreatic exocrine diseases, pancreatic endocrine diseases, and pancreatic cancer. Pancreatic exocrine diseases include pancreatitis, which is an inflammation of the pancreas, and pancreatic insufficiency, which is a condition in which the pancreas does not produce enough digestive enzymes. Pancreatic endocrine diseases include diabetes, which is a condition in which the pancreas does not produce enough insulin, and hormonal disorders such as glucagonoma and insulinoma. Pancreatic cancer is a type of cancer that begins in the cells of the pancreas.

Current Treatment Options

Current treatment options for pancreatic diseases vary depending on the specific condition. Pancreatitis is typically treated with pain relief medication, fasting, and intravenous fluids. Pancreatic insufficiency can be treated with enzyme replacement therapy, which involves taking pancreatic enzyme supplements with meals. Diabetes is typically treated with insulin therapy and dietary changes. Pancreatic cancer is typically treated with surgery, chemotherapy, and radiation therapy.

Drugs in Development by Stage

Drugs in development for pancreatic diseases can be classified into four stages: phase I, phase II, phase III, and phase IV. Phase I trials are designed to test the safety and tolerability of the drug in a small group of healthy volunteers. Phase II trials are designed to test the efficacy of the drug in a small group of patients with the disease. Phase III trials are designed to test the efficacy and safety of the drug in a larger group of patients. Phase IV trials are designed to monitor the long-term safety and efficacy of the drug after it has been approved for use.

Phase I

Some of the drugs in development for pancreatic diseases that are currently in phase I trials include:

  • APG-115: a small molecule inhibitor of MDM2, which is being developed by Ascentage Pharma for the treatment of pancreatic cancer.
  • SEL24/MEN1703: a dual PIM/FLT3 kinase inhibitor, which is being developed by Men
Read more